OBJECTIVES: Upon completion of this activity, the participant should be able to: 

1. Identify patients in primary care who meet evidence‑based criteria for pharmacologic obesity treatment and determine commonly overlooked obesity‑related comorbidities, such as obstructive sleep apnea and metabolic dysfunction–associated steatohepatitis (MASH).
2. Evaluate currently available anti-obesity medications with respect to mechanism of action, clinical efficacy, safety profile, contraindications, and potential benefits for obesity-related comorbid conditions.
3. Apply a patient-centered, comorbidity-focused framework to select appropriate pharmacotherapy for obesity while incorporating individual risk factors, comorbid diseases, and long-term management considerations. 

FACULTY DISCLOSURE: Marlow Griggs, MD, has no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

PLANNER DISCLOSURE: The planners have no relevant financial relationship(s) with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACCREDITATION: The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

DESIGNATION:  The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information, please contact Tove Goldson, MD at [email protected].